- Poster presentation
- Open Access
A new approach for noninvasive assessment of chronic cardiac allograft rejection in rat by cellular cardiac MRI
© Ye et al; licensee BioMed Central Ltd. 2010
Published: 21 January 2010
Long-term cardiac transplant survival rates can be improved only if patients undergo proper monitoring and treatment after transplantation. Repetitive endomyocardial biopsy, the gold standard for monitoring rejection status, is not only invasive but is also prone to sampling errors because of the limited size and location of graft tissue available. We have developed cellular and functional MRI techniques as a non-invasive method to detect and stage acute cardiac allograft rejection. Our recent studies indicate that macrophages can be detected by MRI in our rat model of CCAR. Therefore, we seek to develop CCMRI for non-invasive evaluation of CCAR.
The aim of this study was to investigate the feasibility of using cellular cardiac MRI (CCMRI) for the non-invasive assessment of chronic cardiac allograft rejection (CCAR) in real time using a rat model.
An abdominal heterotopic working heart rat model was used in this study. Immune cells (mainly macrophages) were in-situ labeled by direct i.v. injection of micrometer-sized paramagnetic iron oxide (MPIO) particles one day prior to initial in-vivo MRI. EKG- and respiratory-gated CCMRI were used to longitudinally monitor the accumulation of MPIO-labeled macrophages in the graft at 4.7 Tesla for up to 120 days. Grafts were then harvested and fixed for high-resolution 3D magnetic resonance microscopy (MRM) at 11.7 Tesla. Fluorescence microscopy for dragon-green co-labeled MPIO and pathology were used to verify the in-vivo CCMRI and MRM results.
Macrophage infiltration to the heart graft experiencing CCAR can be serially monitored by MRI following a single i.v. injection of MPIO. Furthermore, the observed increase in MPIO-labeled macrophages correlates with the severity of CCAR and this method provides a non-invasive, real-time and whole-heart assessment of rejection. This study demonstrates the feasibility of non-invasive assessment of CCAR which has great potential in clinical applications.
This article is published under license to BioMed Central Ltd.